![]() |
市場調查報告書
商品編碼
1399642
單純皰疹病毒治療市場 - 依病毒類型(HSV-1、HSV-2)、藥物類型(阿昔洛韋、伐昔洛韋)、部位(口服、生殖器)、給藥途徑(口服、局部)、配銷通路(醫院、零售) , 全球預測,2023-2032Herpes Simplex Virus Treatment Market - By Virus Type (HSV-1, HSV-2), Drug Type (Acyclovir, Valacyclovir), Site (Oral, Genital), Route of Administration (Oral, Topical), Distribution Channel (Hospital, Retail), Global Forecast, 2023-2032 |
由於治療方法的進步、人們對皰疹感染的認知不斷提高以及單純皰疹病毒-2 (HSV-2) 患病率的不斷上升,全球單純皰疹病毒(HSV) 治療市場預計在2023 年至2032 年期間將以4% 的速度成長。2)。
根據世界衛生組織 2023 年的報告,全球 50 歲以下人口中約 67%(37 億)患有 1 型單純皰疹病毒 (HSV-1),導致口腔皰疹。據估計,15-49 歲人群中的 13%(4.91 億)患有 2 型單純皰疹病毒 (HSV-2),從而導致生殖器皰疹。許多單純皰疹病毒感染是無症狀的或未被識別。隨著公眾意識的不斷增強,人們對皰疹病毒的性質、傳播和潛在併發症的了解越來越多。對早期診斷和適當治療的關注促進了對先進治療解決方案的需求。
全球單純皰疹病毒(HSV)治療產業根據病毒類型、藥物類型、部位、給藥途徑、配銷通路和地區進行分類。
由於 HSV-2 病毒類型在全球人口中的盛行率不斷上升,預計在研究期間將持續成長。專注於解決 HSV-2 帶來的具體挑戰的研發活動激增,強調需要針對這種皰疹病毒株獨特特徵的專門治療方案。
由於伐昔洛韋藥物類型能夠透過抑制病毒複製來控制皰疹感染,因此預計到 2032 年將實現穩定成長。作為阿昔洛韋的前藥,伐昔洛韋可增強生物利用度並確保延長抗病毒活性,進而抑制感染。此外,該藥物對 HSV-1 和 HSV-2 均有效,使其成為臨床醫生和患者的首選。
由於皰疹感染盛行率激增,預計亞太地區單純皰疹病毒 (HSV) 治療市場規模將在 2023 年至 2032 年快速擴張,因此需要更加關注治療和管理策略。中國和印度等國家的醫療基礎設施正在取得顯著進展。此外,人們對性傳染感染的認知不斷增強,這增加了對有效的皰疹治療解決方案的需求。該地區有利的醫療保健政策將塑造未來幾年的產業動態。
The global Herpes Simplex Virus (HSV) treatment market is expected to register a 4% growth rate during 2023-2032, propelled by advancements in therapeutic approaches, rising awareness about herpes infections, and a growing prevalence of Herpes Simplex Virus-2 (HSV-2).
As per a WHO report in 2023, about 67% of the global population aged below 50 years (3.7 billion) have herpes simplex virus type 1 (HSV-1), causing oral herpes. An estimated 13% of people aged 15-49 years (491 million) has herpes simplex virus type 2 (HSV-2), leading to genital herpes. Many HSV infections are asymptomatic or go unrecognized. As public awareness builds overtime, individuals are becoming more informed about the nature, transmission, and potential complications associated with herpes viruses. The focus on early diagnosis and appropriate treatments is contributing to the demand for advanced therapeutic solutions.
The global Herpes Simplex Virus (HSV) treatment industry is classified based on virus type, drug type, site, route of administration, distribution channel, and region.
The HSV-2 virus type segment is expected to witness sustained growth during the study period driven by its rising prevalence amongst the global population. There is a surge in R&D activities focused on addressing the specific challenges posed by HSV-2, emphasizing the need for specialized treatment options catering to the unique characteristics of this herpes strain.
The valacyclovir drug type segment is set for steady growth through 2032 owing to its efficacy in managing herpes infections by inhibiting viral replication. As a prodrug of acyclovir, valacyclovir enhances bioavailability and ensures prolonged antiviral activity, thereby curbing the infection. Moreover, the drug is effective against both HSV-1 and HSV-2, making it a preferred choice for clinicians and patients alike.
Asia Pacific Herpes Simplex Virus (HSV) treatment market size is anticipated to witness rapid expansion over 2023-2032, driven by a surge in the prevalence of herpes infections, necessitating increased attention to treatment and management strategies. Countries like China and India are experiencing notable advancements in healthcare infrastructure. Also, there is a growing awareness of sexually transmitted infections, contributing to the demand for effective herpes treatment solutions. The favourable healthcare policies in the region will shape the industry dynamics in the coming years.